Could a common diabetes drug tame gout flares?
NCT ID NCT06674109
First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This study tests whether empagliflozin (Jardiance), a drug used for diabetes, can lower uric acid levels and reduce inflammation in people with gout. Sixty adults with gout and high uric acid will take either the drug or a placebo daily for 12 weeks. Researchers will measure changes in uric acid, inflammation markers, and gout flares to see if a larger trial is worthwhile.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Empagliflozin (Jardiance) 10 mg daily
- What this could lead to
- If it works, this could point toward a new treatment option for gout that also reduces inflammation.
- What could go wrong
- This is a small, early-phase trial with only 60 people over 12 weeks. The results may not lead to a proven treatment, and side effects from empagliflozin are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT AND HYPERURICEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02144, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.